Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sequence-specific transcriptional activators, such as the human factor
E2F-1
, increase the rate of initiation of transcription by RNA polymerase II, possibly by contacting one or more of the RNA polymerase II-associated general initiation factors. One candidate target of transactivators is the
TATA-binding protein
(
TBP
), which, when bound to a promoter, nucleates the formation of a preinitiation complex. Previous studies using affinity chromatography techniques have shown that the activation domains of certain activators, including the acidic activation domain of
E2F-1
, can interact with
TBP
in the absence of DNA. Using a site-directed photoaffinity cross-linking approach, we demonstrate here that the activation domain of the chimeric activator LexA-
E2F-1
can be cross-linked to
TBP
when both factors are bound to a transcriptionally responsive RNA polymerase II promoter. Mutations within the activation domain of LexA-
E2F-1
that impaired its ability to activate transcription in vitro were found to reduce cross-linking of LexA-
E2F-1
to
TBP
. The association of initiation factor TFIIB with the
TBP
-promoter complex did not preclude this promoter-dependent cross-linking to LexA-
E2F-1
; however, this cross-linking was promoter-independent. In contrast, TFIIA strongly inhibited the promoter-dependent cross-linking of LexA-
E2F-1
to
TBP
. These results directly demonstrate that acidic activators such as
E2F-1
can interact with
TBP
during the earliest stages in the assembly of an RNA polymerase II preinitiation complex.
...
PMID:Promoter-dependent photocross-linking of the acidic transcriptional activator E2F-1 to the TATA-binding protein. 777 19
